Literature DB >> 20680028

Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study.

A J Risselada1, J Vehof, R Bruggeman, B Wilffert, D Cohen, A F Al Hadithy, J Arends, H Mulder.   

Abstract

In two previous studies we found an association between HTR2C polymorphisms and the prevalence of the metabolic syndrome in patients using antipsychotics. In this study, we set out to replicate our findings in a third separate sample of patients. Data for this cross-sectional study came from the ongoing Pharmacotherapy Monitoring and Outcome survey study, investigating the association between schizophrenia and metabolic or cardiovascular risk factors. Primary end point was the prevalence of the metabolic syndrome. Primary determinants were two polymorphisms in the HTR2C gene: rs3813929 (-759 C/T) and rs1414334:C>G. Carriership of the variant rs1414334 C-allele was significantly associated with an increase prevalence of the metabolic syndrome (odds ratio (OR) 3.73; 95% confidence interval (CI) 1.29-10.79, P=0.015). No association was found between the HTR2C -759 C/T polymorphism and the metabolic syndrome. This study confirms previous findings that the variant C-allele of the rs1414334 polymorphism is associated with the metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20680028     DOI: 10.1038/tpj.2010.66

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  14 in total

1.  Insights into the influence of 5-HT2c aminoacidic variants with the inhibitory action of serotonin inverse agonists and antagonists.

Authors:  Roberta Galeazzi; Luca Massaccesi; Francesco Piva; Giovanni Principato; Emilioano Laudadio
Journal:  J Mol Model       Date:  2014-02-22       Impact factor: 1.810

Review 2.  Genetics of Common Antipsychotic-Induced Adverse Effects.

Authors:  Raymond R MacNeil; Daniel J Müller
Journal:  Mol Neuropsychiatry       Date:  2016-05-20

3.  Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.

Authors:  Marc DE Hert; Christoph U Correll; Julio Bobes; Marcelo Cetkovich-Bakmas; Dan Cohen; Itsuo Asai; Johan Detraux; Shiv Gautam; Hans-Jurgen Möller; David M Ndetei; John W Newcomer; Richard Uwakwe; Stefan Leucht
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

4.  A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.

Authors:  Davy Vancampfort; Martien Wampers; Alex J Mitchell; Christoph U Correll; Amber De Herdt; Michel Probst; Marc De Hert
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

Review 5.  Psychiatric drugs impact mitochondrial function in brain and other tissues.

Authors:  Shawna T Chan; Michael J McCarthy; Marquis P Vawter
Journal:  Schizophr Res       Date:  2019-11-16       Impact factor: 4.939

6.  Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review.

Authors:  Gavin P Reynolds
Journal:  Clin Psychopharmacol Neurosci       Date:  2012-08-31       Impact factor: 2.582

7.  Genetic Polymorphisms in the HTR2C and Peroxisome Proliferator-Activated Receptors Are Not Associated with Metabolic Syndrome in Patients with Schizophrenia Taking Clozapine.

Authors:  Shi Hyun Kang; Jong Il Lee; An Kee Chang; Yeon Ho Joo; Chang Yoon Kim; Seong Yoon Kim
Journal:  Psychiatry Investig       Date:  2011-05-26       Impact factor: 2.505

8.  Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication.

Authors:  Jelle Vehof; Arne J Risselada; Asmar F Y Al Hadithy; Huibert Burger; Harold Snieder; Bob Wilffert; Johan Arends; Lex Wunderink; Henrikus Knegtering; Durk Wiersma; Dan Cohen; Hans Mulder; Richard Bruggeman
Journal:  Psychopharmacology (Berl)       Date:  2011-02-19       Impact factor: 4.530

Review 9.  Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics.

Authors:  John Lally; Fiona Gaughran; Philip Timms; Sarah R Curran
Journal:  Pharmgenomics Pers Med       Date:  2016-11-07

10.  Association between the HTR2C rs1414334 C/G gene polymorphism and the development of the metabolic syndrome in patients treated with atypical antipsychotics.

Authors:  José María Rico-Gomis; Antonio Palazón-Bru; Irene Triano-García; Luis Fabián Mahecha-García; Ana García-Monsalve; Andrés Navarro-Ruiz; Berta Villagordo-Peñalver; Jessica Jiménez-Abril; Alicia Martínez-Hortelano; Vicente Francisco Gil-Guillén
Journal:  PeerJ       Date:  2016-07-07       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.